Omadacycline for the Treatment of Severe Chlamydia psittaci Pneumonia Complicated with Guillain-Barre Syndrome
Juan Wang,Shuangyong Dong,Mengjuan Fang,Zhiyan Fan,Yuansheng Xu
DOI: https://doi.org/10.2147/idr.s437100
2024-01-10
Infection and Drug Resistance
Abstract:Juan Wang, Shuangyong Dong, Mengjuan Fang, Zhiyan Fan, Yuansheng Xu Department of Emergency, Affiliated Hangzhou First People`s Hospital, School of Medicine, Westlake University, Hangzhou, People's Republic of China Correspondence: Yuansheng Xu, Department of Emergency, Affiliated Hangzhou First People`s Hospital, School of Medicine, Westlake University, No. 261 Huansha Road, Hangzhou, Zhejiang Province, 310006, People's Republic of China, Email Background: Chlamydia psittaci ( C. psittaci ) is a pathogen that is seldom implicated in community-acquired pneumonia and is rarely linked to severe pneumonia. Reports of severe C. psittaci pneumonia accompanied by Guillain-Barre syndrome (GBS) are scarce. Tetracyclines are the preferred therapeutic approach for psittacosis. Omadacycline, a novel tetracycline, demonstrates strong antibacterial efficacy against typical bacteria and atypical pathogens, including C. psittaci . However, its application in the treatment of psittacosis pneumonia remains constrained. Case Presentation: A 77-year-old female patient was admitted to the hospital presenting with symptoms of fever, low back pain, and headache. The diagnosis of C. psittaci was established through the utilization of metagenomic next-generation sequencing (mNGS). Initial administration of moxifloxacin, meropenem, piperacillin-tazobactam, and doxycycline proved to be ineffective. Subsequent omadacycline leaded to the successful resolution of fever and dyspnea. However, after the endotracheal tube was removed, the patient experienced a rapid decline in symmetrical limb strength, leading to a diagnosis of GBS based on clinical manifestations, cerebrospinal fluid analysis, and electromyography. Following a 5-day course of immunoglobulin therapy and nutritional nerve treatment, the patient's condition ameliorated, culminating in an uncomplicated discharge. Conclusion: This case provides evidence supporting the potential use of omadacycline as a therapeutic option for the treatment of severe C. psittaci pneumonia. The utilization of mNGS technology is of paramount importance in the prompt identification of uncommon pathogens, including C. psittaci . Nevertheless, the occurrence of GBS should be taken into consideration when C. psittaci pneumonia is accompanied by symmetrical limb weakness. These findings have important implications for the diagnosis, treatment, and management of patients with C. psittaci pneumonia. Keywords: Chlamydia psittaci pneumonia, Guillain-Barre syndrome, omadacycline, metagenomic next‐generation sequencing Chlamydia psittaci ( C. psittaci ) is classified within the order Chlamydia and is an obligate intracellular parasite within the chlamydia family. This family derives its name from its propensity to parasitize birds belonging to the psittaci family. 1 Inhalation serves as the primary mode of infection transmission, while prolonged exposure to infected avian species such as chickens, ducks, geese, and other poultry can also result in infection. The clinical manifestations of psittacosis exhibit a lack of specificity, with various systems of the entire body being susceptible to its effects. These effects can range from mild flu-like symptoms to severe and life-threatening conditions such as acute respiratory distress syndrome, rhabdomyolysis, Guillain-Barre syndrome (GBS), and multiple organ failure. 2 GBS, a disease of the peripheral nervous system, is induced by post-infection and autoimmune factors. 3 Instances of C. psittaci pneumonia associated with GBS have been rarely documented. While tetracyclines are the preferred treatment for psittacosis, their efficacy may be limited in cases of severe C. psittaci pneumonia complicated by GBS and liver and kidney involvement. Omadacycline is a novel semi-synthetic tetracycline developed by Paratek Pharmaceutical in the United States. 4 It has been found to have a broad antibacterial spectrum and has great antibacterial activity against atypical bacteria such as C. psittaci , 5 however, there is a scarcity of clinical literature regarding the use of omadacycline in the treatment of psittacosis. 6 In this report, we present a case of severe C. psittaci pneumonia accompanied by GBS that was successfully treated with omadacycline, resulting in a favorable prognosis. The patient was admitted to the hospital on October 12, 2022, with a fever for 5 days, low back pain, and headache for 3 days. Five days before admission, the patient received no treatment with a fever, chills, and fatigue. Three days ago, the patient developed a high fever, expiratory dyspnea, and experienced back pain and headach -Abstract Truncated-
pharmacology & pharmacy,infectious diseases